N4 Pharma (N4P) Share Price, News & Analysis

Company Overview

N4 Pharma is a biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases. RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage. N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners. N4 Pharma’s lead programme, N4 101, is an oral anti-inflammatory product for inflammatory bowel disease (IBD) which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform. With an estimated 10 million people globally suffering from Crohn’s disease and ulcerative colitis, the IBD treatment market was worth $20.4bn in 2023 and is expected to grow by a CAGR of 3.9% to over $27.6bn by 2030, driven by both increased incidences of the disease and development of new treatments. click here to visit our investor hub https://investors.n4pharma.com/

Key Stats

• Today's Range: 0.45 to 0.48
• 50-Day Range: 0.46 to 0.75
• 52-Week Range: 0.37 to 0.95
• Volume: 1.51 million shs
• Average Volume: 2.26 million shs
• Market Capitalization: £2.02 million
• P/E Ratio: N/A
• Dividend Yield: 3.12%
• Price Target: N/A
• Consensus Rating: N/A

N4P Stock Analysis - Frequently Asked Questions

How have N4P shares performed this year?

N4 Pharma's stock was trading at GBX 0.54 at the beginning of the year. Since then, N4P shares have decreased by 12.3% and is now trading at GBX 0.47.
View the best growth stocks for 2025 here.

How were N4 Pharma's earnings last quarter?

N4 Pharma Plc (LON:N4P) announced its earnings results on Thursday, September, 17th. The company reported ($0.48) earnings per share (EPS) for the quarter. N4 Pharma had a negative net margin of 18,399.86% and a negative trailing twelve-month return on equity of 90.68%.

How do I buy shares of N4 Pharma?

Shares of N4P stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of N4 Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that N4 Pharma investors own include 4D pharma (DDDD), Active Energy Group (AEG), B&M European Value Retail (BME), BP (BP), Coats Group (COA), EQTEC (EQT) and genedrive (GDR).

Company Calendar

• Last Earnings: 9/17/2020
• Today: 3/29/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: LON:N4P
• CIK: N/A
• Web: www.n4pharma.com
• Phone: +44-1332-690061
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.35)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-1,626,800.60
• Net Margins: -18,399.86%
• Pretax Margin: N/A
• Return on Equity: -90.68%
• Return on Assets: -56.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 22.73
• Quick Ratio: 7.28

Sales & Book Value

• Annual Sales: £8,841.37
• Price / Sales: 228.45
• Cash Flow: GBX 0.21 per share
• Price / Cash Flow: 2.25
• Book Value: GBX 0.45 per share
• Price / Book: 1.05

Miscellaneous

• Outstanding Shares: 430,669,091
• Free Float: N/A
• Market Cap: £2.02 million
• Optionable: Not Optionable
• Beta: -0.37